Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05246267 · ClinicalTrials.gov registry record
Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis
A clinical trial of Chronic Rhinosinusitis With Nasal Polyps, sponsored by Montefiore Medical Center.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT05246267 is a study of Chronic Rhinosinusitis With Nasal Polyps that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 60 participants, below the 137-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05246267, a study of Chronic Rhinosinusitis With Nasal Polyps, is actively recruiting participants, sponsored by Montefiore Medical Center.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The central hypothesis of this study is that the addition of dupilumab treatment onto standard-of-care intranasal corticosteroids will improve patient-reported measures of disease activity and sense of smell in a cohort of mostly ethnical and racial minority patients with CRSwNP
Conditions Studied
Interventions
- BIOLOGICAL Dupilumab
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2026-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05246267
The ClinicalTrials.gov registry entry for NCT05246267 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (56% lower). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Rhinosinusitis With Nasal Polyps appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT05246267 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05246267 about?
NCT05246267 is a clinical study titled "Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis". The central hypothesis of this study is that the addition of dupilumab treatment onto standard-of-care intranasal corticosteroids will improve patient-reported measures of disease activity and sense of smell in a cohort of mostly ethnical and racial minority patients with CRSwNP
What is the current status of trial NCT05246267?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2022-02-15. Estimated completion is 2026-06.
What conditions does trial NCT05246267 study?
This clinical trial studies the following conditions: Chronic Rhinosinusitis With Nasal Polyps.
What interventions are being tested in trial NCT05246267?
The interventions under investigation include: Dupilumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05246267?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05246267 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Rhinosinusitis With Nasal Polyps
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
RECRUITING · Phase 3
-
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
RECRUITING · Phase 2
-
The Role of IL5 in Epithelial Cell Integrity
RECRUITING · Early Phase 1
-
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
RECRUITING · Phase 3
-
3D Printing to Improve Nasal Irrigation Outcome
RECRUITING · NA
-
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.